{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341270","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2026-08-10T11:40:52+00:00","discovered_at":"2026-08-10T11:45:00.371098+00:00","generated_at":"2026-08-10T11:45:06.226673+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jazz to acquire Actio Biosciences for $820M upfront, up to $500M milestones","bullets":["Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in approval/sales milestones.","Lead asset ABS-1230: first-in-class KCNT1 inhibitor for KCNT1+ epilepsy, no FDA-approved therapies.","ABS-1230 has FDA Fast Track, Rare Pediatric Disease, Orphan Drug designations; accepted into RDEP program.","Transaction expected to close Q4 2026; funded via cash on hand and existing facilities.","Actio spins out new entity with TRPV4 inhibitor ABS-0871; Jazz takes minority stake."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341270","json":"https://secwatch.observer/filing/0001193125-26-341270.json","markdown":"https://secwatch.observer/filing/0001193125-26-341270.md","text":"https://secwatch.observer/filing/0001193125-26-341270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/0001193125-26-341270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/d106596d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:45:06.226673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}